Financial PerformanceAtea reported a net loss of $34.3 million, or a loss of $0.40 per share, which was similar to an estimate of a loss of $36.0 million, or a loss of $0.42 per share.
Operational ChallengesPatient adherence and cirrhotic status remain challenges in the treatment of HCV.
Workforce ReductionA workforce reduction by 25% is planned during the first quarter, which could lead to roughly $15 million in cost savings through 2027.